OncoMatch

OncoMatch/Clinical Trials/NCT06485778

A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

Is NCT06485778 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for oral tongue squamous cell carcinoma.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06485778Data as of May 2026

This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out if this approach affects the rate of disease coming back after treatment (recurrence), and will measure participants' quality of life by having them complete questionnaires.

Check if I qualify

Extracted eligibility criteria

Disease stage

Required: Stage PT1, PT2, PT3 BY DOI, PN0, PN1, PN2B

Excluded: Stage N2C, PT3 BY SIZE

pT1-2, or pT3 by DOI, pN0-2b Squamous Cell Carcinoma of the Oral Tongue confirmed on final surgical pathology. Exclusion: N2c/N3 nodal disease, pT3 by size

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk - Commack · Commack, New York
  • Memorial Sloan Kettering Westchester · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify